Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with obesity or overweight, but without diabetes: The SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 3-year trial

Publication date: January–February 2019Source: Obesity Research & Clinical Practice, Volume 13, Issue 1Author(s): Tania Markovic, Arne Astrup, Frank Greenway, Michel Krempf, Carel W. Le Roux, Roberto Vettor, Linda Shapiro Manning, Søren K. Lilleøre, Ken Fujioka

Source: Obesity Research and Clinical Practice - February 9, 2019 Category: Eating Disorders & Weight Management Source Type: research